Objective:To analyze the research programs of clinical trials related to the TCM treatment of Hashimoto's thyroiditis (HT) at home and abroad; To provide references for the follow-up study of TCM treatment of HT.Methods:All clinical research registration plans for TCM prevention and treatment of HT were retrieved from the Chinese Clinical Trial Registry, the International Traditional Medicine Clinical Trial Registry, and the WHO International Clinical Trial Registration Platform from the establishment of the databases to December 31, 2024. Excel 2019 and GraphPad Prism 9.0 were used for data processing, and the basic characteristics, study types, randomized methods, interventions, outcome indicators and other registration information of registered trials with the frequency analysis.Results:A total of 31 clinical trials were included in this study, and the number of registered studies has gradually increased since 2018, which involving 23 clinical institutions in 9 provincial-level administrative regions until 2024. The region with the highest number of registrations is Shanghai (14 items). The funding sources were mainly local financial support and hospital funding. The research types were mostly intervention studies (30 items). The main research design type was randomized parallel controlled trials (27 items).Conclusions:At present, the overall number of registration studies on TCM prevention and treatment of HT is relatively small. However, in recent years, researchers have paid more attention to the registration of clinical trials in this field. The regional distribution of existing trial registration is not balanced, and the research design scheme needs to be improved.

Objective:To compare the efficacy of peripheral and central transcranial magnetic stimulation (rTMS) in the treatment of functional constipation.Methods:Sixty patients with functional constipation were randomly divided into a control group, a peripheral group and a central group, each of 20. All were given oral lactulose medication, while the peripheral groups was additionally provided with high-frequency repetitive magnetic stimulation (rMS) treatment in the sacral region (S2-4) and the central group received low-frequency rTMS treatment in the right dorsal prefrontal cortex. Before and after 3 weeks of treatment, all were evaluated in terms of the average weekly frequency of spontaneous complete bowel movements (SCBM), major constipation symptom scoring, and using the Constipation Patient Symptom Self Rating Scale (PAC-SYM).Results:After the treatment, all of the indicators had improved significantly in all three groups, but all were better in the peripheral and central groups than in the control group, on average. The peripheral group and the central group averages were not significantly different after the treatment. The total effectiveness rates in the peripheral and central groups both exceeded 90%, significantly better than among the control group.Conclusions:Both peripheral high-frequency rTMS and central low-frequency rTMS can effectively supplement lactulose drug treatment in relieving the symptoms of constipation.

Objective:To compare the efficacy of peripheral and central transcranial magnetic stimulation (rTMS) in the treatment of functional constipation.Methods:Sixty patients with functional constipation were randomly divided into a control group, a peripheral group and a central group, each of 20. All were given oral lactulose medication, while the peripheral groups was additionally provided with high-frequency repetitive magnetic stimulation (rMS) treatment in the sacral region (S2-4) and the central group received low-frequency rTMS treatment in the right dorsal prefrontal cortex. Before and after 3 weeks of treatment, all were evaluated in terms of the average weekly frequency of spontaneous complete bowel movements (SCBM), major constipation symptom scoring, and using the Constipation Patient Symptom Self Rating Scale (PAC-SYM).Results:After the treatment, all of the indicators had improved significantly in all three groups, but all were better in the peripheral and central groups than in the control group, on average. The peripheral group and the central group averages were not significantly different after the treatment. The total effectiveness rates in the peripheral and central groups both exceeded 90%, significantly better than among the control group.Conclusions:Both peripheral high-frequency rTMS and central low-frequency rTMS can effectively supplement lactulose drug treatment in relieving the symptoms of constipation.

Vaccination is a main measure for protecting chickens against Marek's disease,while it is not able to suppress the infection,proliferation,transmission,and virulence enhancement on Marek's disease virus.Inhibiting the proliferation of Marek's disease virus in chicken is therefore an im-portant option for enhancing defense effectiveness.In this study,a compound,DUBs-IN-1,was found to inhibit the activity of MDV049,a protease encoded by Marek's disease virus,via screening a protease inhibitor library using MDV049 as target and ubiquitin probe.Molecular docking re-vealed that DUBs-IN-1 can interact with the residues which formed the catalytic pocket of MDV049,blocking the interaction between Ub substrate and the catalytic center of MDV049,then suppress the activity of MDV049 with competitive inhibition.Using the CPE model,it was found that DUBs-IN-1 at the concentration of 0.35 and 0.70 μmol/L significantly inhibited the CPE in-duced by Marek's disease virus in CEF cells.Quantitative analysis revealed that DUBs-IN-1 inhibi-ted the proliferation of Marek's disease virus in CEF cells(P＜0.01).Furthermore,it was found that the administration of 80 and 150 pg/(kg·d)of DUBs-IN-1 in chicken infected by Marek's disease virus significantly inhibited the proliferation of MDV in T cells(P＜0.01).In summary,this study demonstrated that the compound DUBs-IN-1 is able to inhibit the proliferation of Marek's disease virus in chicken cells,laying a theoretical and practical foundation for further de-velopment of the drugs against Marek's disease virus.